What does Sun Pharma’s approval for generic semaglutide in South Africa mean for diabetes care? Here’s how it could improve access to affordable treatment.
Sun Pharmaceutical Industries has secured marketing approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa, marking a significant milestone in the company’s global diabetes portfolio. The approval positions South Africa as the second market after India where Sun Pharma has received regulatory clearance for its generic semaglutide. ()
The generic medicine has been approved for the treatment of adults with inadequately controlled type 2 diabetes mellitus, to be used alongside diet and exercise to improve blood sugar control. Sun Pharma said it plans to launch the product in the South African market in the coming days.
Advertisement
Available in Pre-filled Injectable Pens
According to the company, the product will be marketed as a pre-filled, multi-dose injectable pen in 2 mg and 4 mg strengths, administered once weekly. The formulation is designed to offer a convenient dosing option for adults managing type 2 diabetes.
Semaglutide belongs to the GLP-1 receptor agonist class of medicines, which help lower blood sugar by stimulating insulin release, suppressing glucagon secretion, slowing gastric emptying, and reducing appetite. The drug is the active ingredient in Novo Nordisk’s blockbuster brands Ozempic and Wegovy, which are used for type 2 diabetes and weight management, respectively.
Advertisement
Patent Expiry Opens the Market
The approval follows the expiry of Novo Nordisk’s semaglutide patent in South Africa in March 2026, creating an opportunity for generic manufacturers to enter the market. Growing global demand for GLP-1 medicines has increased interest in affordable alternatives, particularly in countries where access has been limited by the high cost of branded therapies.
Industry analysts expect increased competition in the South African market as more pharmaceutical companies introduce generic versions of semaglutide over the coming months. Reuters reported that the generic will compete not only with Novo Nordisk’s Ozempic but also with Eli Lilly’s Mounjaro, another widely prescribed GLP-1 therapy.
Advertisement
Company Highlights Access to Affordable Medicines
Commenting on the approval, Sun Pharma said the milestone reflects its capability to develop complex generic medicines that meet stringent regulatory standards across international markets. The company added that it remains committed to expanding patient access to evidence-based treatment options through affordable generic medicines.
Why Semaglutide Matters
Semaglutide has transformed the treatment landscape for type 2 diabetes and obesity over the past few years. By improving blood glucose control and promoting weight loss, it has become one of the world’s most sought-after medicines. However, the high cost of branded products has restricted access for many patients, especially in low- and middle-income countries.
The availability of generic semaglutide is expected to improve affordability and broaden access to treatment for people living with type 2 diabetes. Increased competition may also help reduce healthcare costs while expanding treatment options for physicians and patients.
Growing Global Generic Opportunity
South Africa joins India among the first countries where generic semaglutide has become commercially available following patent expiry. Several pharmaceutical companies are pursuing approvals in other international markets as intellectual property protections expire over the coming years, signaling the beginning of a more competitive global market for GLP-1 therapies.
References:
- Sun Pharma receives approval to manufacture and market generic semaglutide in South Africa – (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://sunpharma.com/wp-content/uploads/2026/07/Sun-Pharma-Semaglutide-Approval-in-SA.pdf)
Source-Medindia